Emerging Systemic Therapy Options beyond CDK4/6 Inhibitors for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

0
99
The authors describe the findings from clinical trials using small molecule inhibitors, antibody–drug conjugates and immunotherapy, providing insights into how these novel strategies may circumvent treatment resistance.
[npj Breast Cancer]
Full Article